{"id":28210,"date":"2026-03-09T12:43:15","date_gmt":"2026-03-09T12:43:15","guid":{"rendered":"https:\/\/www.europesays.com\/ch\/28210\/"},"modified":"2026-03-09T12:43:15","modified_gmt":"2026-03-09T12:43:15","slug":"biopharma-dealmaking-in-2025","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ch\/28210\/","title":{"rendered":"Biopharma dealmaking in 2025"},"content":{"rendered":"<p> Dealmaking continued to be a key part of company strategies to address challenges facing the biopharma industry in 2025, including drug pricing pressures, a difficult biotech funding market and the need for large companies to replenish their pipelines ahead of loss of exclusivities on major products. Here, we cover mergers and acquisitions (M&amp;As) and partnerships in the biopharma industry last year, as well as consumer and over-the-counter industries, drug delivery technologies, contract research, and clinical trial services, but excluding devices, diagnostics, research tools, animal health, and insurance.<\/p>\n<p>                Enjoying our latest content? <br \/>Log in or create an account to continue<\/p>\n<p>                Access the most recent journalism from Nature&#8217;s award-winning team<br \/>\n                Explore the latest features &amp; opinion covering groundbreaking research<\/p>\n<p class=\"app-access-wall__option-separator\">or<\/p>\n<p>                    Competing Interests<\/p>\n<p>The authors declare no competing interests.<\/p>\n","protected":false},"excerpt":{"rendered":"Dealmaking continued to be a key part of company strategies to address challenges facing the biopharma industry in&hellip;\n","protected":false},"author":2,"featured_media":28211,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[124],"tags":[4091,336,6719,584,17088,17089,17087,134],"class_list":{"0":"post-28210","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-roche","8":"tag-biomedicine","9":"tag-biotechnology","10":"tag-cancer-research","11":"tag-general","12":"tag-medicinal-chemistry","13":"tag-molecular-medicine","14":"tag-pharmacology-toxicology","15":"tag-roche"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ch\/116199280119520092","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/28210","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=28210"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/28210\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/28211"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=28210"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=28210"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=28210"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}